Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

Ludwig Kappos; Robert J. Fox; Michel Burcklen; Mark S. Freedman; Eva Havrdová

doi:10.1001/jamaneurol.2021.0405

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

Ludwig Kappos, Robert J. Fox, Michel Burcklen, Mark S. Freedman, Eva Havrdová, Bryan T. Hennessy, Reinhard Hohlfeld, Fred Lublin, Xavier Montalbán, Carlo Pozzilli, Tatiana Scherz, Daniele D’Ambrosio, Philippe Linscheid, Andrea Vaclavkova, Magdalena Pirozek-Lawniczek...

American Medical Association (2021) • Volume 78, Issue 5, Pages 558-558

PDF Available

Abstract

ClinicalTrials.gov Identifier: NCT02425644.

Quick Actions

Read Full Paper

Publication Info

DOI

10.1001/jamaneurol.2021.0405

Language

English

Topic

Multiple Sclerosis Research Studies

Keywords

Teriflunomide, Multiple sclerosis, Medicine, Internal medicine, Fingolimod, Immunology

Published

March 29, 2021

Citations

200 citations

FWCI

31.00

External Resources

DOI Link OpenAlex

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

Abstract

Quick Actions

Publication Info

External Resources

Suggested Papers

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Suggested Papers

Suggested Papers

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy